M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
CMOs showed an increasing reluctance to take on debt in 2022
CMOs showed an increasing reluctance to take on debt in 2022
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Urges Innovators to produce quality products that can be deployed at scale
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Subscribe To Our Newsletter & Stay Updated